To evaluate the impact of right ventricular dysfunction (RVD) on outcome after transcatheter mitral valve repair (TMVR) in patients with chronic heart failure (CHF) and severe functional mitral regurgitation (FMR).
| INTRODUCTION
Mitral regurgitation (MR) is the second most frequent valvular heart disease in industrialized countries, 1 leading to worsening heart failure, pulmonary hypertension, atrial fibrillation, and death. 2 Thus, in the absence of surgical repair, severe MR has a poor prognosis. 3 In patients with chronic heart failure (CHF), left ventricular (LV) dysfunction is often accompanied by functional mitral regurgitation (FMR). FMR is caused by incomplete leaflet coaptation due to regional or global LV remodeling with otherwise structurally preserved mitral valve leaflets. 4 Severe FMR in this setting is associated with worse outcome. 5, 6 However, up to 50% of patients with severe MR are denied surgery due to advanced age, reduced left ventricular ejection fraction (LV-EF), and multiple comorbidities. 7 Furthermore, the prognostic benefit of surgical mitral valve repair for FMR is controversial since the rates of perioperative mortality and recurrent MR are not negligible. 8, 9 Therefore, the percutaneous transcatheter mitral valve repair (TMVR) using the MitraClip system (Abbott Vascular, Abbott Park, IL) has been established as an alternative treatment strategy for patients with severe MR who are denied surgery or considered at high risk for conventional mitral valve surgery. [10] [11] [12] The Endovascular Valve
Edge-to-Edge Repair Study (EVEREST II) demonstrated superior safety and similar clinical improvement of TMVR compared with surgery in low-or intermediate-risk patients with predominantly degenerative MR. 13 Subsequent observational studies and registries confirmed the feasibility and clinical efficacy of TMVR also in high-surgical-risk patients with a high prevalence of clinically significant FMR secondary to CHF. 10, 11, [14] [15] [16] [17] [18] [19] FMR is often accompanied by a right ventricular dysfunction (RVD) because of the pressure overload and changes in the pulmonary vasculature caused by the chronically elevated leftsided filling pressures. A concomitant RVD is associated with increased mortality in patients admitted with heart failure. 20 Furthermore, in patients with severe FMR who are referred to surgery, RVD is a predictor of postoperative survival. 21 The influence of RVD on outcome in patients with CHF and severe FMR treated with the MitraClip is, however, still unclear. Thus, the aim of this retrospective observational study was to evaluate the impact of RVD on outcome in CHF patients with severe FMR who underwent percutaneous TMVR using the MitraClip system.
| METHODS
From March 2013 to April 2015, all consecutive patients with New
York Heart Association (NYHA) functional class III or IV suffering from moderate-to-severe or severe FMR 22 due to CHF were included into the study. CHF was defined as heart failure with reduced ejection fraction ≤45%. FMR was defined as MR caused by incomplete leaflet coaptation due to regional or global LV remodeling with otherwise structurally preserved mitral valve leaflets.
Patients undergoing TMVR were enrolled if they were judged inoperable or at unacceptable high-surgical-risk based on the logistic European System for Cardiac Operative Risk Evaluation (log EuroSCORE) and if they had a favorable anatomy suitable for the MitraClip procedure.
The suitability was determined by a heart team decision. All patients included in the study were fully informed about the procedure and signed a written consent form. All patients received optimal medical and device treatment at least 3 months prior to the MitraClip procedure according to the current heart failure guidelines. 23 The cohort was divided into two groups depending on the right ventricular (RV) function assessed by the tricuspid annular plane systolic excursion (TAPSE) method. 24 A reduced RV function (Group A) was defined as a TAPSE ≤16 mm. A normal RV function (Group B) was defined as a TAPSE >16 mm.
Transthoracic and transesophageal echocardiographic evaluations were performed at baseline. Transthoracic echocardiographic evaluations were performed at pre-discharge, 30 days postprocedural and, if possible, at follow-up. Severity grade of MR at baseline was assessed according to the current guidelines. 22, 25 Acute procedural success was reported as well as periprocedural and in-hospital major adverse events such as death, failed clip defined as unsuccessful clip placement, myocardial infarction, major stroke, renal failure with the need for renal replacement therapy, pericardial tamponade with the need for pericardiocentesis, urgent or emergent cardiovascular surgery for adverse events, bleeding complications with the need for blood transfusion, and surgical re-operation for sustained MR. The postprocedural length of mechanical ventilation on the intensive care unit was also analyzed.
All follow-up evaluations were conducted at the Bremen heart center. If a patient was not able to be present at follow-up, a telephonic interview was conducted with either the patient himself, the patient's relatives, or general practitioner. Major adverse cardiac and cerebrovascular events (MACCE) were analyzed including death, major stroke, non-fatal myocardial infarction, and surgical or interventional (TMVR) re-do for sustained or recurrent severe MR. Changes in functional capacity, categorized by the NYHA functional class, were assessed as well as a state of health self-assessment based on a standardized health-related quality of life questionnaire (EQ-5D). The all-cause mortality and the rate of hospital readmission due to congestive heart failure were evaluated at 30 days postprocedural and after a median follow-up period of 10.5 ± 4 months.
We conducted a baseline invasive hemodynamic study in all included patients during the screening phase in a conscious nonsedated state. Right heart catheterization was performed using a 6 F single lumen, balloon-tipped, flow directed Swan-Ganz catheter (Arrow International, Inc., Reading, PA). All values were reported at end-expiration.
All procedures were performed under general anesthesia using (3D) transesophageal echocardiographic and fluoroscopic guidance.
The percutaneous edge-to-edge repair with the MitraClip was performed as previously described. 10, 13 Parametric/non-parametric distribution of data was assumed by .000 ng/L). A two-sided P value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 22 (SPSS, Inc., Chicago, IL).
| RESULTS
A total of 130 consecutive patients (Group A: n = 58; Group B: n = 72) were enrolled (Table 1) . Mean age of all patients was 72.7 ± 10.7 years. A total of 63.8% were male, with a trend towards a higher proportion of male patients in group A. Patients in group A were more likely to have a history of CABG, whereas the rate of previous PCI was higher in group B. Patients in group A presented a higher LogEuroSCORE and higher levels of NT-proBNP. Chronic atrial fibrillation was more prevalent in group A. The proportion of patients suffering from NYHA functional class IV was similar in both groups.
The degree of MR severity was similar in both groups (Table 2) .
Both groups had similarly reduced LV-EF. A concomitant severe tricuspid valve regurgitation was more common in group A.
Hemodynamic data did not differ significantly between groups,
showing a post-capillary pulmonary hypertension with a similarly reduced cardiac index ( Table 3 ).
The pulmonary vascular resistance was equivalently elevated in both groups.
The rate of successful MR reduction (MR ≤2 at discharge) was high and similar in both groups (94.6% vs 91.2%; P: n.s., Table 1 ). In 6 out of Table 4 ). The numbers of clips implanted were similar in both groups (Table 1) .
Five patients (3.8%) died during the hospital stay (Table 4) One patient (group B) needed a mitral valve replacement for failed TMVR due to partial clip detachment 1 day after the procedure.
Patients with RVD needed more often a postprocedural mechanical ventilation longer than 48 h (Table 4) .
Clinical follow-up was obtained in all included patients (100%). A total of 13 patients (10%) died 30 days after the procedure (6 in group A, 7 in group B). All six patients in group A died due to cardiac reasons. Among the seven deceased patients in group B, four patients (57.1%) died due to cardiac causes and three patients (42.9%) died due to non-cardiac reasons. The rate of all-cause mortality 30 days after TMVR was equal in both groups (10.3% vs 9.7%; P: n.s.). Furthermore, 13 patients (10%) were rehospitalized due to congestive heart failure (6 in group A, 7 in group B). Thus, the rate of hospital readmission due to congestive heart failure 30 days postprocedural did not differ significantly between the groups (10.3% vs 9.7%; P: n.s).
During the mean follow-up period of 10. with group B (43.1% vs 23.6%, log-rank P = 0.039, Figure 1 ).
By Cox proportional hazards regression analysis, RVD
(TAPSE ≤ 16 mm, DTI-S' ≤ 9.5 cm/s) was an independent predictor of all-cause mortality ( Figure 2 ). 
| DISCUSSION
This study compared the impact of RVD on outcome in patients with CHF and symptomatic FMR undergoing TMVR. The results of our study showed that substantial RVD was associated with higher rates of all-cause mortality and hospital readmission due to congestive heart failure at long-term follow-up. RVD was an independent predictor of all-cause mortality. Similarly, more patients with RVD declared in a self FIGURE 2 Multivariate Cox proportional hazards regression analysis for all-cause mortality adjusted for severely reduced LV-EF (≤30%), TAPSE ≤16 mm, DTI-S' ≤9.5 cm/s, atrial fibrillation, CABG, NT-proBNP levels ≥10.000 ng/L, TR severity grade III°F IGURE 3 Kaplan-Meier estimate of rehospitalization rate due to congestive heart failure. Kaplan-Meier analysis demonstrated a significantly higher rate of rehospitalization due to congestive heart failure in group A compared with group B FIGURE 4 Distributions of NYHA functional class according to the right heart function (Group A: TAPSE ≤16 mm; Group B: TAPSE >16 mm) before the procedure (NYHA pre) and at follow-up (NYHA follow-up); mean follow-up period: 10.5 ± 4 months after the MitraClip implantation. Numbers in columns denote percentage of patients assessment that they did not benefit symptomatically from TMVR.
Consequently, more patients with RVD remained in NYHA functional classes III and IV as compared with CHF patients with preserved RV function.
Independently from the RV function, we observed a high acute procedural success rate with low rate of in-hospital major adverse events. These results are like other multicenter registries including a large cohort of real-world patients. 17, 19 Our findings underline the excellent early safety profile and procedural feasibility of TMVR, even in high surgical risk patients. However, it should be taken into consideration that patients with RVD needed more often a postprocedural mechanical ventilation longer than 48 h on an intensive care unit.
In our study, the observed rate of all-cause mortality (32%) at follow-up was higher compared with data from other real-world registries like TRAMI (20.3%) and ACCESS-EU (17.3%). One reason might be the higher proportion of patients with a more advanced heart failure and the frequency of the pre-existing multiple risk factors as it is expressed in a significantly higher log EuroSCORE. Thus, the mortality rate observed in this study is comparable to other studies focusing especially on high surgical risk candidates treated with MitraClip.
11,14
Indeed, Orban et al 26 assessed the long-term outcome in patients with severe biventricular heart failure and severe MR undergoing TMVR showing a high mortality rate (50%) 8 month after TMVR. It has been postulated, that there might be a subgroup of patients with an unfavorable outcome. In fact, patients with an impaired RV function together with a pulmonary hypertension showed a high 1-year mortality rate (77%).
Furthermore, several studies tried to identify predictors of outcome after TMVR. It has been observed that beside a NYHA functional class IV, high levels of NT-proBNP, and a severely reduced LV-EF, a reduced RV function as assessed by TAPSE (≤15 mm) and DTI-S' (≤9.5 cm/s) could be an independent predictor of adverse outcome. 16, 27 These findings are comparable with the results of our study showing also an unfavorable long-term outcome in patients with RVD. The overall rate of readmission due to congestive heart failure detected in our study is somewhat higher than observed in other registries and studies. 17, 18, 28 These results seemed to be mainly driven by the significantly higher rate of readmission in the subgroup of patients with RVD. Consequently, the rate of readmission due to congestive heart failure in the subgroup of patients with preserved RV 
| Study limitations
The retrospective study is limited by its single-center, observational design and selection bias cannot be completely excluded since group A had more patients with previous CABG and atrial fibrillation, which both could contribute to impaired RVD at baseline. However, as a strength of the investigation, the impact of RV function on outcome is evaluated in a "real-world" cohort of severely ill patients without any classical exclusion criteria usually used in randomized studies.
| CONCLUSION
The percutaneous edge-to-edge mitral valve repair using the MitraClip system is a safe and effective treatment option to improve symptoms and quality of life in CHF patients at high operative risk, especially in that subgroup of patients with preserved RV function. Despite a high acute procedural success rate with low periprocedural and in-hospital major adverse events, CHF patients with RVD showed an unfavorable longterm outcome in terms of survival and readmission due to congestive heart failure. RVD as assessed by TAPSE and DTI-S' predicts all-cause mortality independent of other important clinical and echocardiographic factors in this cohort of patients. Thus, CHF patients with RVD seem to benefit less frequently from the MitraClip procedure. Therefore, patients with RVD should be screened carefully to select the most appropriate candidates who benefit most from TMVR.
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